Customization: | Available |
---|---|
CAS No.: | 2521-07-5 |
Formula: | C12h10n2 |
Still deciding? Get samples of US$ 10/Grams
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name
|
9-Me-BC CAS:2521-07-5 / 9-Methyl-9H-beta-carboline
|
CAS
|
2521-07-5
|
Appearance
|
light yellow powder
|
Grade
|
USP BP FCC EP
|
MW
|
495.73
|
Usage
|
Active Pharmaceutical Ingredient
|
Storage
|
Keep in cool & dry place, stay away from strong light and heat
|
Shelf Life
|
24 months
|
Application:
9-Me-BC is a known inhibitor of monoamine oxidase A and monoamine oxidase B, and has been proposed for further investigation in the treatment of Parkinson's disease.
Benefits:
Tests have shown that NSI-189 significantly improved behavioral responses that are associated with depression . In humans it may counter hippocampal atrophy which is seen in disorders such as MDD, reversing their symptoms. A phase 1B randomized, double-blind, placebo-controlled, multiple-dose escalation study conducted over a 28 day period showed behavioral efficacy in 24 patients who were orally administered NSI-189 . The efficacy measurements showed a clinically meaningful reduction in cognitive and depressive symptoms across all measures, and appeared to persist over time during follow up for the efficacy assessments which included the Clinical Global Impression - Improvement (CGI-I), Montgomery-Aserb Depression Rating Scale (MADRS), Cognitive and Physical Functioning Questionnaire (CPFQ, and the Symptoms of Depression Questionnaire (SDQ) .